Charles Schwab Investment Management Inc. Has $64.49 Million Stock Holdings in Penumbra, Inc. (NYSE:PEN)

Charles Schwab Investment Management Inc. lifted its stake in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 271,574 shares of the company's stock after purchasing an additional 3,807 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.71% of Penumbra worth $64,493,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. True Wealth Design LLC bought a new stake in shares of Penumbra in the 3rd quarter worth approximately $26,000. UMB Bank n.a. raised its holdings in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after acquiring an additional 70 shares during the period. Mather Group LLC. lifted its position in shares of Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after acquiring an additional 208 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company's stock worth $81,000 after purchasing an additional 43 shares during the period. Finally, Jones Financial Companies Lllp grew its position in Penumbra by 25.0% during the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several research analysts recently weighed in on PEN shares. Piper Sandler reissued an "overweight" rating and set a $330.00 price target (up from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Truist Financial increased their price target on shares of Penumbra from $285.00 to $325.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Royal Bank of Canada raised their target price on Penumbra from $285.00 to $313.00 and gave the company an "outperform" rating in a report on Wednesday, February 19th. Wells Fargo & Company upped their price target on Penumbra from $275.00 to $305.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Finally, Canaccord Genuity Group boosted their target price on shares of Penumbra from $323.00 to $340.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $292.64.

Insider Buying and Selling at Penumbra

In other Penumbra news, CEO Adam Elsesser sold 61,600 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total value of $17,469,144.00. Following the completion of the transaction, the chief executive officer now directly owns 16,376 shares of the company's stock, valued at approximately $4,644,069.84. The trade was a 79.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Johanna Roberts sold 600 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00. Following the completion of the sale, the executive vice president now directly owns 66,539 shares of the company's stock, valued at approximately $19,125,304.77. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,918 shares of company stock worth $22,054,293 over the last ninety days. Corporate insiders own 5.00% of the company's stock.

Penumbra Price Performance

Shares of PEN stock traded down $6.38 during trading hours on Thursday, hitting $260.75. The company had a trading volume of 281,756 shares, compared to its average volume of 397,283. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The firm's fifty day moving average is $268.84 and its 200 day moving average is $236.72. The firm has a market capitalization of $10.04 billion, a price-to-earnings ratio of 766.91, a PEG ratio of 2.83 and a beta of 0.51.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. The firm had revenue of $315.52 million for the quarter, compared to analysts' expectations of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. On average, sell-side analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.